Skip to main content

Table 2 Participants performance during the 12 weeks of training

From: A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers

  All Walk Strength-walk
Adherence (%) 67 (58–75) 61 (56–72) 69 (63–79)
Total walked distance (Km) 122 (84–146) 105c (73–139) 136c (121–155)
Total energy expenditure (KJ/Kg)a 298.18 (205.31-356.84) 248.84 (173.00-329.84) 344.67 (306.65-392.82)
Walked distance/session (m) 5040 (4380–5500) 4740d (3535–5390) 5330d (4980–5700)
Energy expenditure per session (KJ/Kg)a 12.32 (10.10-14.28) 11.23 (8.01-13.77) 13.51 (12.09-15.25)
HRmean (% of HRmax)b 66 (62–75) 66 (58–73) 70 (63–86)
  1. Values as expressed as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test
  2. aCalculation was based on the U shape relationship between walking metabolic cost and speed [43]
  3. bThe median HRmean value was calculated for each participant through all her/his walking sessions, to derive the median HRmean value of all participants
  4. cWalk vs. strength-walk group, p = 0.029 (Mann–Whitney test)
  5. dWalk vs. strength-walk group, p = 0.027 (Mann–Whitney test)
  6. No significant differences were observed between the two training groups for adherence, total and per session energy expenditure, and HRmean
  7. HR heart rate